Dr Gary E Caplan, MD, MPH | |
1213 15th Ave. W., Williston, ND 58801-3821 | |
(701) 572-7651 | |
Not Available |
Full Name | Dr Gary E Caplan |
---|---|
Gender | Male |
Speciality | Preventive Medicine - Occupational Medicine |
Location | 1213 15th Ave. W., Williston, North Dakota |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164470043 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083X0100X | Preventive Medicine - Occupational Medicine | 4792122-1205 (Utah) | Secondary |
2083X0100X | Preventive Medicine - Occupational Medicine | 10624 (North Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Gary E Caplan, MD, MPH 1301 15th Ave. W., Williston, ND 58801-3821 Ph: (701) 774-7400 | Dr Gary E Caplan, MD, MPH 1213 15th Ave. W., Williston, ND 58801-3821 Ph: (701) 572-7651 |
News Archive
MicroRNAs are the newest kid on the genetic block. By regulating the unzipping of genetic information, these tiny molecules have set the scientific world alight with such wide-ranging applications as onions that can't make you cry and therapeutic potential for new treatments for viral infections, cancer and degenerative diseases. But the question remains: How do they work?
Eating a diet that is rich in fruits, vegetables and whole grains and low in added sugar, sodium and processed meats could help promote healthy cellular aging in women, according to a new study published in the American Journal of Epidemiology.
The Food and Drug Administration today announced the publication of the new FDA Food Code, a model code and reference document that provides a scientifically sound technical and legal basis for regulating the retail and food service segment of the food industry. The 2009 FDA Food Code is a key component of the President's overall public-health-focused food safety framework for maintaining a safe food supply.
AFRESA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, according to data presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes.
› Verified 9 days ago